MedTrace Logo

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

NCT06410300 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2025-06-19

No results posted yet for this study

Summary

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Conditions

Interventions

RADIATION

Curative Radiotherapy

Radiation dose of 45 Gy or higher

DRUG

Immunotherapy

checkpoint inhibitor per PI discretion

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Bo Lu

    lead OTHER

Principal Investigators

  • Bo Lu, MD · Chair, Department of Radiation Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2028-04-19
Completion
2030-04-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06410300 on ClinicalTrials.gov